Johanna Mercier - Gilead Sciences Chief Commercial Officer

GILD34 Stock  BRL 287.56  4.47  1.58%   

Executive

Ms. Johanna Mercier is Chief Commercial Officer of the Company since 2019.
Age 53
Tenure 5 years
Professional MarksMBA
Phone650 574 3000
Webhttps://www.gilead.com
Mercier is a proven leader who brings to Gilead deep experience in worldwide and senior operational roles in geographies around the globe. She has held leadership positions in therapeutic areas including oncology, inflammation and neuroscience. She joins Gilead from BristolMyers Squibb, where she most recently served as President and Head of the company Large Markets division, which includes the United States, France, Germany and Japan. Over the course of her career, she has helped drive growth across key markets, pioneered innovative access strategies in the United States and Europe and helped establish new standards of care for people with cancer. In addition to her executive position at BristolMyers, Ms. Mercier is a director on the Robert Wood Johnson University Hospital Board. She holds a MBA from Concordia University and a BSs in Biology from the University of Montreal.

Johanna Mercier Latest Insider Activity

Tracking and analyzing the buying and selling activities of Johanna Mercier against Gilead Sciences stock is an integral part of due diligence when investing in Gilead Sciences. Johanna Mercier insider activity provides valuable insight into whether Gilead Sciences is net buyers or sellers over its current business cycle. Note, Gilead Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gilead Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Gilead Sciences Management Efficiency

The company has return on total asset (ROA) of 0.1045 % which means that it generated a profit of $0.1045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.216 %, meaning that it generated $0.216 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities.
Gilead Sciences has accumulated 25.18 B in total debt with debt to equity ratio (D/E) of 117.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has a current ratio of 3.68, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Gilead Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Gilead Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gilead Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gilead to invest in growth at high rates of return. When we think about Gilead Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

EXECUTIVE Age

Jennifer ZacharyMerck Co
45
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people. Gilead Sciences (GILD34) is traded on Sao Paulo Exchange in Brazil and employs 31 people.

Management Performance

Gilead Sciences Leadership Team

Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel ODay, Chairman of the Board, CEO
Johanna Mercier, Chief Commercial Officer
Deborah Telman, Gen Affairs
Jyoti Mehra, Ex HR
Jacquie CFA, VP Relations
Diane Wilfong, Corp VP
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Michael Quigley, VP Biology
Linda Higgins, VP Innovation

Gilead Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Gilead Stock

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.